



Acarix resolves on a directed issue to the guarantors of the warrant series 3

Acarix AB ("Acarix" or the "Company") today announces that the Board of Directors has resolved on a directed issue to the guarantors of the warrant of series 3 (TO3) in accordance with the agreements entered into prior the exercise period of the said warrants. In accordance with the outcome of the warrant exercise, published on September 26, 2024, the guarantors have been allocated 3,415,857 shares to the corresponding terms as the TO3 exercise, i.e. SEK 0.25 per share. Thus, Acarix will receive proceeds of approximately SEK 0.9 million through the directed issue (before issuing costs).

The directed issue

As announced on August 28, 2024, Acarix entered into guarantee agreements which, together with declarations of intent, fully secured the exercise of the TO3 warrants. According to the terms in the agreements the guarantors agreed to subscribe for the number of shares corresponding to unexercised warrants in the TO3 series. According to the guarantee agreements, the subscription price for guarantors should be the same as the exercise price for the TO3 warrants, which was set to SEK 0.25 (according to the formula in the warrant terms). The guarantors include Life Science Invest Fund, Nowo Global Fund, Wilhelm Risberg, Fredrik Lundgren, Bernhard von der Osten-Sacken, and CA Own 2 AB. The reason to deviate from the shareholders' preemptive right is to fulfill the Company's obligation in accordance with the guarantee agreements.

As shown by the outcome of the exercise of warrants of series 3 announced on September 26, 2024, a total of 96.2 percent was subscribed by TO3 warrant holders, meaning that 3,415,857 shares should be issued and subscribed for by the guarantors. The proceeds from the new shares correspond to approx. SEK 0.9 million. To fulfill the agreements, the Board of Directors has decided to resolve on the directed issue, as authorized by the annual general meeting on May 14, 2024.

Number of shares, share capital and dilution

Through the directed share issue to the guarantors, the number of shares will increase by 3,415,857 shares to 1,063,743,780 shares (calculated as the number of shares after the issuance of shares subscribed for by the exercise of warrants of series 3). The share capital will increase by SEK 34,158.57, to SEK 10,637,437.80.

The distribution of shares to the guarantors will take place once the directed share issue has been registered with the Swedish Companies Registration Office.

The dilution for existing shareholders amounts to approximately 0.3 percent.



Advisers

Advokatfirman Lindahl KB is acting as legal advisor and Penser by Carnegie, Carnegie Investment Bank is acting as financial advisor in connection with the directed issue.

IMPORTANT INFORMATION

The release, announcement or distribution of this press release may, in certain jurisdictions, be subject to restrictions. The recipients of this press release in jurisdictions where this press release has been published or distributed shall inform themselves of and follow such legal restrictions. The recipient of this press release is responsible for using this press release, and the information contained herein, in accordance with applicable rules in each jurisdiction. This press release does not constitute an offer, or a solicitation of any offer, to buy or subscribe for any securities in Acarix in any jurisdiction, neither from Acarix nor from someone else.

This press release is not a prospectus for the purposes of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 (the "Prospectus Regulation") and has not been approved by any regulatory authority in any jurisdiction.

This announcement does not identify or suggest, or purport to identify or suggest, the risks (direct or indirect) that may be associated with an investment in the Company.

This press release does not constitute or form part of an offer or solicitation to purchase or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States absent registration or an exemption from registration under the US Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold within the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public offer of the securities in the United States. The information in this press release may not be announced, published, copied, reproduced or distributed, directly or indirectly, in whole or in part, within or into the USA, Australia, Belarus, Canada, Hong Kong, Japan, New Zealand, Russia, Singapore, South Africa, South Korea, Switzerland or in any other jurisdiction where such announcement, publication or distribution of the information would not comply with applicable laws and regulations or where such actions are subject to legal restrictions or would require additional registration or other measures than what is required under Swedish law. Actions taken in violation of this instruction may constitute a crime against applicable securities laws and regulations.

For more information contact:

Jennifer Monies, phone +1 (405) 550-8144, jmonies@saxum.com



About Acarix

Acarix is a Swedish medical device company that innovates solutions for rapid rule out of coronary artery disease (CAD) at point of care. The CE-approved and FDA DeNovo-cleared Acarix CADScor System is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive, and costly diagnostic procedures. The CADScor System has been used on more than 29,000 patients. Acarix recommends CADScor System as a first-line diagnostic aid that uses highly sensitive acoustics and advanced computational processing to analyze coronary blood flow to rule out significant coronary artery disease (CAD), with at least 96% certainty at point of care. Acarix is listed on the Nasdaq First North Premier Growth Market in Stockholm (ticker: ACARIX) and cross-traded on the OTCQB market in the US (ticker: ACIXF). Carnegie Investment Bank is the Certified Advisor of Acarix. For more information, please visit www.acarix.com

Attachments

[Acarix resolves on a directed issue to the guarantors of the warrant series 3](#)